PLAU and cancer: Neutralizing antibodies against urokinase plasminogen activator (uPA) or urokinase plasminogen activator receptor (uPAR) inhibited adhesion of the cancer cells to the mesothelial layer, while blocking PAI-1 had the opposite effect [40].